eznews.inAs measles cases surge in the U.S. and other countries, health officials are emphasizing the importance of vaccinations, particularly for travelers. The Centers for Disease Control and Prevention (CDC) has urged international travelers to ensure they are fully vaccinated against measles, as the disease is highly contagious and can spread rapidly in confined spaces like planes and buses. Experts recommend that individuals check their vaccination status and consider booster shots if they received only one dose or an inactivated vaccine. The MMR vaccine provides lifelong protection, and travelers should aim to get vaccinated at least two weeks prior to their journey. Additional safety measures include wearing masks, practicing good hygiene, and maintaining distance from those who may be infected. Symptoms of measles typically appear within 7 to 14 days and may lead to severe complications, underscoring the need for prompt medical attention if exposed. 
Published: Jul 01 2025, 12 ameznews.inA recent study challenges the long-held belief that omega-3 and omega-6 fatty acids are primarily anti-inflammatory, suggesting instead that they may be linked to increased levels of certain inflammatory markers in the blood. Researchers analyzed data from over 15,000 participants in two large cohorts, the Avon Longitudinal Study of Parents and Children (ALSPAC) and the UK Biobank, employing a genetic technique called Mendelian randomization to explore causality. Findings indicated that higher levels of omega-3 and omega-6 fatty acids were associated with elevated GlycA, a marker of low-grade chronic inflammation. The study emphasizes the importance of the omega-6 to omega-3 ratio, which has shifted dramatically in modern diets, potentially contributing to chronic diseases. While the results suggest a more complex relationship between these fatty acids and inflammation, experts call for further research to explore additional biomarkers and the broader implications for dietary recommendations.
Published: Jun 29 2025, 6 pmeznews.inA recent study presented at the European Academy of Neurology Congress has unveiled a simple blood test that measures insulin resistance, potentially aiding in predicting cognitive decline in individuals with early-stage Alzheimer’s disease. Currently, there is no effective tool to forecast the progression speed of Alzheimer’s, making this discovery significant. Researchers analyzed data from 315 adults, finding that those with higher insulin resistance, as indicated by the triglyceride-glucose (TyG) index, faced a fourfold increased risk of rapid cognitive deterioration. This low-cost, easily accessible test could help clinicians identify patients at higher risk, allowing for timely interventions and personalized treatment strategies. Experts emphasize the importance of early detection, as it could enhance the effectiveness of current medications and lifestyle modifications. Moving forward, researchers aim to explore the correlation between the TyG index and neuroimaging biomarkers to refine risk assessments further.
Published: Jun 28 2025, 5 pmeznews.inSwedish researchers from the Karolinska Institute and Stockholm University have developed a promising new oral drug aimed at treating type 2 diabetes and obesity without the muscle loss associated with existing GLP-1 medications like Ozempic. The drug, which operates through skeletal muscle metabolism, was tested in a phase 1 clinical trial involving 73 participants, including those with diabetes. Results showed good tolerance, with only mild, transient increases in heart rate observed early in the trial. Unlike GLP-1 drugs, which can reduce lean muscle mass by up to 60%, this new medication preserves muscle mass, crucial for maintaining strength and metabolic rate during weight loss. Experts, including Dr. Mir Ali and Dr. Maria Knöbel, emphasize the importance of preserving muscle to enhance glucose control and improve long-term diabetes outcomes. Following these encouraging results, researchers plan to conduct a more extensive phase 2 trial.
Published: Jun 27 2025, 3 pmeznews.inA recent study has linked the consumption of instant coffee to an increased risk of developing age-related macular degeneration (AMD), a leading cause of vision loss affecting approximately 200 million people worldwide. Conducted by researchers from Hubei University of Medicine, the study analyzed data from over 500,000 participants, identifying a genetic correlation between instant coffee consumption and dry AMD risk, which was found to be sevenfold higher compared to other coffee types. While AMD primarily occurs due to aging and genetic factors, modifiable lifestyle choices like diet can influence its progression. The findings suggest potential biological pathways connecting instant coffee consumption to AMD, raising questions about dietary impacts on eye health. Experts emphasize the need for further research to validate these associations and explore the broader implications of processed foods on health. Current recommendations remain cautious, pending more direct evidence linking instant coffee to AMD.
Published: Jun 26 2025, 12 pmeznews.inA recent study presented at the Sleep 2025 conference has raised concerns about the implications of daytime napping for middle-aged and older adults. Researchers found a correlation between increased daytime napping and a higher risk of all-cause mortality, suggesting that napping may indicate underlying health issues rather than being a direct cause of mortality. The study, which analyzed data from over 86,000 participants in the UK Biobank, revealed that those who napped longer and more irregularly had a greater likelihood of death during an eight-year follow-up. Experts emphasize the importance of considering daytime sleep patterns as potential markers of health decline, advocating for further research into the relationship between napping and mortality. They recommend strategies for improving nighttime sleep quality, such as establishing consistent sleep schedules and managing medical conditions, to reduce the need for daytime naps.
Published: Jun 25 2025, 11 pmeznews.inA recent study suggests that semaglutide, the active ingredient in the diabetes medications Ozempic and Wegovy, may help reduce the risk of dementia, particularly vascular dementia, among individuals with type 2 diabetes. Researchers analyzed health records of over 1.7 million adults, finding that semaglutide effectively targets multiple dementia risk factors, including obesity, diabetes, and cardiovascular issues, while also exhibiting anti-inflammatory properties that could mitigate dementia progression. Although the findings indicate a protective association, they do not establish causation. Experts emphasize the importance of targeting modifiable risk factors, as around 50% of dementia cases are preventable. The study's lead author, Dr. Rong Xu, noted that further research is needed to explore the long-term effects of semaglutide and other GLP-1 medications. This research could potentially inform treatment options for diabetes that also address cognitive health, highlighting the interconnectedness of metabolic and brain health.
Published: Jun 24 2025, 9 pmeznews.inResearchers have developed a novel hybrid biomaterial that may slow or reverse heart aging by focusing on the extracellular matrix (ECM), a crucial component that supports cell structure and function. A study published in *Nature Materials* highlights the ECM's role in age-related cardiac dysfunction, revealing that changes in its mechanics and composition contribute to the stiffening of heart muscles. The team created a high-tech model, DECIPHER, which allows for independent control of ECM stiffness and biochemical signals, demonstrating that the biochemical environment significantly influences heart cell function. While promising, these findings, based on rat cells, require further validation before potential human applications. Experts suggest lifestyle changes, such as regular aerobic exercise, a healthy diet, smoking cessation, adequate sleep, weight management, and stress reduction, to support heart health as one ages. Reducing alcohol intake is also recommended to mitigate risks associated with heart disease.
Published: Jun 24 2025, 5 pmeznews.inResearch into longevity has gained momentum, particularly with a meta-analysis published in *Aging Cell* revealing that the drug rapamycin may extend lifespan in various vertebrate species, comparable to dietary restrictions. The study, which synthesized data from 167 papers involving animals such as mice and monkeys, found that while dietary restriction consistently promotes longevity, metformin showed minimal effects. Rapamycin, originally an immunosuppressant, demonstrated significant potential for life extension, but its efficacy in humans remains untested. Researchers caution against premature use of rapamycin until human trials confirm safety and efficacy, particularly given its side effects. Future studies may refine rapamycin into safer derivatives, known as rapalogs, to maximize benefits while minimizing risks. Despite the promising findings, experts emphasize the need for comprehensive human trials to better understand the implications of these medications on human lifespan.
Published: Jun 24 2025, 12 ameznews.inA recent study presented at the European Academy of Neurology Congress suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, commonly used to treat type 2 diabetes and obesity, may significantly reduce migraine days for patients suffering from chronic migraines. Led by Dr. Simone Braca from the University of Naples, the pilot study involved 31 participants who took liraglutide, a GLP-1 medication, and reported an average decrease of nine migraine days per month. Participants also experienced a 32-point reduction in their Migraine Disability Assessment Test scores, indicating improved quality of life. Researchers hypothesize that GLP-1 agonists may help by regulating intracranial pressure, a key factor in migraine pathophysiology. While the findings are promising, experts urge caution, highlighting the need for larger, randomized studies to confirm these results and explore the potential of other GLP-1 drugs in migraine treatment.
Published: Jun 23 2025, 6 pmFor the fastest, latest, not so wokest news, 'experts say' you need to visit Eznews
India
World
Economy
Science
Health
Showbiz
Contact